| 证券代码：300705 | 证券简称：九典制药 | 公告编号：2025-061 | | --- | --- | --- | | 债券代码：123223 | 债券简称：九典转 02 | | 湖南九典制药股份有限公司 关于改变募集资金用途的公告 本公司及董事会全体成员保证向本公司提供的信息内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 湖南九典制药股份有限公司（以下简称"公司""九典制药"）于 2025 年 8 月 21 日召开第四届董事会第十二次会议和第四届监事会第八次会议，审议通 过了《关于改变募集资金用途的议案》，同意公司结合政策和市场环境变化、整 体经营布局调整等实际情况，改变向不特定对象发行可转换公司债券募集资金用 途。本议案不涉及关联交易，尚需提交股东会审议。现将有关事项公告如下： 经中国证券监督管理委员会出具的《关于同意湖南九典制药股份有限公司向 不特定对象发行可转换公司债券注册的批复》（证监许可[2021]62 号）的核准， 公司向不特定对象发行不超过人民币 270,000,000.00 元的可转换公司债券。本 次向不特定对象发行可转换公司债券，每张面值为人民币 100 元，发行 ...

| 编制单位：湖南九典制药股份有限公司 | | | | | | | | | | 金额单位：人民币万元 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 非经营性资金占 | 资金占用方名称 | 占用方与上市公 | 上市公司核算的 | 2025年初占用资 | 2025年1-6月占用累计发 | 2025年1-6月占用资 | 2025年1-6月偿 | 2025年6月末占 | 占用形成原因 | 占用性质 | | 用 | | 司的关联关系 | 会计科目 | 金余额 | 生金额（不含利息） | 金的利息（如有） | 还累计发生额 | 用资金余额 | | | | 控股股东、实际 控制人及其附属 | | | | | | | | | | 非经营性占用 | | 企业 | | | | | | | | | | 非经营性占用 | | 小 计 | —— | —— | —— | | | | | | —— | —— | | 前控股股东、实 际控制人及其附 | | | | | | | | | | 非经营性占用 | | 属企业 | | | | | | | ...

Core Insights - The company announced the acquisition of all developed results and corresponding intellectual property of JIJ02 gel from Chengdu Ped Bio-pharmaceutical Co., Ltd. for 90 million yuan [1] - The company has completed the transfer procedures for the clinical approval documents related to the product [1] Group 1 - The acquisition amount for the JIJ02 gel is 90 million yuan [1] - The original name of the gel was "PD-DP-008 gel" [1] - The company signed a technology transfer contract with Chengdu Ped [1]

九典制药（SZ 300705，收盘价：19.87元）8月21日晚间发布公告称，为进一步丰富产品线，湖南九典 制药股份有限公司以9,000万元受让成都佩德生物医药有限公司拥有的JIJ02凝胶（原申报名称"PD-DP- 008 凝胶"）的全部已开发成果及相应知识产权，并签署了《技术转让合同书》。 2024年1至12月份，九典制药的营业收入构成为：药品制剂占比80.43%，原料药占比7.81%，药用辅料 占比6.69%，植物提取物及其他占比3.73%，技术转让及服务占比1.29%。 （文章来源：每日经济新闻） ...

Core Viewpoint - Jiutian Pharmaceutical (300705.SZ) has acquired all developed results and corresponding intellectual property rights of JIJ02 gel from Chengdu Ped Bio-Pharmaceutical Co., Ltd. for 90 million yuan, aiming to enrich its product line [1] Group 1 - The acquisition amount is 90 million yuan [1] - The acquired product is JIJ02 gel, previously known as "PD-DP-008 gel" [1] - A technology transfer contract has been signed between the two companies [1]

| 证券代码：300705 | 证券简称：九典制药 | 公告编号：2025-055 | | --- | --- | --- | | 债券代码：123223 | 债券简称：九典转02 | | 湖南九典制药股份有限公司 关于受让取得药物临床试验批准通知书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 为进一步丰富产品线，湖南九典制药股份有限公司（以下简称"公司"）以 9,000 万元受让成都佩德生物医药有限公司（以下简称"成都佩德"）拥有的 JIJ02 凝胶（原申报名称"PD-DP-008 凝胶"）的全部已开发成果及相应知识产权，并 签署了《技术转让合同书》。 本次交易不构成关联交易，亦不构成《上市公司重大资产重组管理办法》规 定的重大资产重组。本次交易无需提交董事会和股东会审议。近日，公司与成都 佩德完成了临床批件转让手续。现将有关事项公告如下： 一、临床试验通知书基本情况 药品名称：JIJ02 凝胶（原申报名称"PD-DP-008 凝胶"） 注册分类：化学药品 1 类 受理号：CXHL2401082 拟定适应症：寻常痤疮 审批结论：根据《中华人民共和国 ...

证券之星消息，8月21日化学制药板块较上一交易日上涨0.09%，*ST苏吴领涨。当日上证指数报收于 3771.1，上涨0.13%。深证成指报收于11919.76，下跌0.06%。化学制药板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 600200 | *ST苏吴 | 0.96 | 5.49% | 43.67万 | | 4141.60万 | | 300705 | 九典制药 | 19.87 | 4.97% | 52.35万 | | 10.35 Z | | 300573 | 兴齐眼药 | 67.48 | 4.69% | 22.77万 | | 15.19 Z | | 688506 | 百利天恒 | 324.96 | 4.21% | 1.62万 | | 5.23亿 | | 002940 | 昂利康 | 51.36 | 3.86% | 15.16万 | | 7.69亿 | | 002020 | 京新药业 | 19.52 | 2.90% | 32.05万 | | 6.16 ...

格隆汇8月21日｜昂利康、九典制药、康泰生物涨超6%，兴齐眼药涨超5%，君实生物、阳光诺和、荣 昌生物涨超3%。 | 代码 | 名称 | 涨幅% ↓ | 总市值 | 年初至今涨幅%。 | | --- | --- | --- | --- | --- | | 002940 | 昂利康 | 6.59 | 106亿 | 301.09 | | 300705 | 九典制药 | 6.39 | 101亿 | 14.43 | | 300601 | 康泰生物 | 6.14 | 210亿 | 10.48 | | 300573 | 兴齐眼药 | 5.71 | 167亿 | 38.45 | | 600200 | *ST苏吴 | 5.49 | 6.82亿 | -89.70 | | 002424 | 贵州百灵 | 4.79 | 88.75亿 | 64.94 | | 430047 | 诺思兰德 | 3.94 | 80.25亿 | 153.77 | | 300147 | ST香雪 | 3.81 | 75.65亿 | 17.09 | | 688180 | 君实生物-し | 3.44 | 476亿 | 69.67 | | 688621 | 阳光诺 ...

Core Insights - Liuyang Economic Development Zone has been recognized as one of the "Top Ten Investment-attractive Parks for 2025" in Hunan Province, reflecting its strong investment attraction and business environment [1] - In the first half of the year, the zone's industrial added value grew by 12.7% year-on-year, and fixed asset investment increased by 14.5%, with industrial technology transformation investment surging by 71.1% [1] - The zone successfully introduced 52 projects with a contractual investment amount exceeding 22 billion yuan, achieving over half of its annual target of 100 projects [1] Administrative-driven Policies - The administrative-driven investment strategy relies on "fund leverage" and "policy guidance" to set the tone for project introductions [3] - Policies have been optimized to support the medical device industry, including rewards for companies obtaining product registration and production licenses [3][4] - The zone has introduced measures to support emerging industries and future industries, focusing on project-driven development [4] Market-driven Initiatives - Market-driven investment strategies are led by Jinyang Investment Group, which has established a focus on investment financing, urban operation, and industrial cultivation [6] - The group has partnered with nearly 20 private equity investment institutions, participating in 29 funds with a total scale exceeding 20 billion yuan [7] - The proportion of projects attracted through fund-driven initiatives has increased from 10-20% to 80-90% [7] Business Environment Optimization - The zone emphasizes a collaborative approach to project implementation, ensuring that companies receive comprehensive support upon settling [9][10] - The "simulated approval" process has expedited project timelines, reducing the average construction cycle by 40 days [10] - A "three-person service" model provides dedicated support to each enterprise, enhancing satisfaction rates to 100% [10] Future Outlook - With the acceleration of the 3 billion yuan mother fund and the expansion of reforms like "immediate construction upon land acquisition," the zone is poised for continued success in attracting investments [11]

Group 1 - The company primarily serves domestic clients, with foreign clients representing a smaller business volume [2] - Domestic clients mainly consist of large commercial distribution companies [2]